100, 100: Breakthrough T1D Research Leads to a New Class of Glucose-Lowering Agents
You’ve seen the ads: Victoza®. Ozempic®. Trulicity®. But did you know that these drugs came about, in part, because of type 1 diabetes research?
100, 100: Genetically Engineered Human Insulin Created
In 1976, researchers set out to synthesize the human insulin gene and make human insulin, and Breakthrough T1D researchers had multiple hands in the biosynthesis of it.
Insulin Affordability? Yes, Please: Breakthrough T1D Joins Civica to Make Low-Cost Insulin Available to All Americans
In conjunction with leading partners, Breakthrough T1D lends its support to Civica, to help combat a nationwide insulin affordability crisis.
Tandem Diabetes Makes Managing T1D More Convenient
Tandem announced the FDA clearance of bolus insulin dosing from their t:connect® mobile app. Soon, individuals with the Tandem t:slim X2™ pump will be able to bolus remotely from either their iOS or Android smartphone.
FDA Approval of Senseonics Eversense® CGM for Use for Up to 6 Months
FDA approves Senseonics Eversense® E3, the first long-term implantable CGM system, and the E3 includes technology that extends the use for up to 6 months.
100 Years, 100 Breakthrough T1D Scientists: The BB Rat—An Animal Model of Type 1 Diabetes
In 1974, a colony of non-diabetic BB rats develops diabetes. Examination of their pancreases revealed that they had no beta cells.
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
FDA Authorizes a Fourth Artificial Pancreas System
The FDA authorized the Insulet Omnipod 5, the world’s first tubeless, wearable system for people 6 and older, using an algorithm that began by Breakthrough T1D funding.
Interview with our New Community Screening and Clinical Trial Education Director
Breakthrough T1D has a new community screening and clinical trials education director. She's been a volunteer and now staff since her daughter was diagnosed in 2002.
New Study Shows Kids 1+ Benefit from Artificial Pancreas Technology
A new paper published in the New England Journal of Medicine shows hybrid closed loop systems help children as young as 1 year old achieve better glycemic control.
